Hospira's bid to crack the lucrative U.S. market for generic biotechnology drugs is running into resistance from its north suburban neighbors Abbott Laboratories and Baxter International Inc.
Abbott, Baxter gang up on Hospira in battle over generics
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.